SRPT earnings: real EPS beat/miss history, analyst consensus Buy, P/E 25.52. Updated 2026-07-23.
Sarepta Therapeutics (SRPT) Research Hub
Sarepta Therapeutics (SRPT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 20.45 USD (-7.13%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 25.52, market cap 1.68B. This hub links to the full technical, earnings and options research available for SRPT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 20.45 USD (-7.13%) |
| 52-week range | 14.84 USD – 23.34 USD |
| Trend regime | Range |
| 14-day RSI | 63.8 (Bullish) |
| Trailing P/E | 25.52 |
| Market cap | 1.68B |
| Dividend yield | 0.00% |
Available research for SRPT
Covered Call on SRPT: how it works, illustrative setup around the real 20.45 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SRPT: how it works, illustrative setup around the real 20.45 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SRPT: how it works, illustrative setup around the real 20.45 USD price, max profit/loss, breakeven and when to use it. Educational.
SRPT technical analysis: range, last 20.45 USD, RSI 63.8, 52w range 14.84 USD–23.34 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SRPT in?
Sarepta Therapeutics (SRPT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SRPT in an uptrend or downtrend?
As of 2026-09-11, SRPT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SRPT's trailing P/E ratio?
SRPT's trailing P/E is 25.52, with a market cap of 1.68B. See the earnings research page for full valuation detail.